STIM - Neuronetics, Inc.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
3.9700
-0.2200 (-5.25%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close4.2700
Open4.1400
Bid0.0000 x 1200
Ask0.0000 x 3000
Day's Range3.9400 - 4.1400
52 Week Range3.9400 - 18.4500
Volume87,969
Avg. Volume158,382
Market Cap70.086M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
All
News
Press Releases
  • GlobeNewswire

    Neuronetics Appoints Andrew Macan As Senior Vice President, General Counsel, Chief Compliance Officer and Corporate Secretary

    Neuronetics, Inc. (STIM), a commercial stage medical technology company focused on designing, developing and marketing products that improve the quality of life for patients who suffer from psychiatric disorders, today announced it has expanded its executive leadership team by adding Andrew Macan as its new Senior Vice President, General Counsel, Chief Compliance Officer and Corporate Secretary effective January 21, 2020. “A proven leader with more than 10 years of experience holding executive team roles at multiple corporations, Andrew is an exciting addition to the Neuronetics team,” said Chris Thatcher, President and Chief Executive Officer of Neuronetics.

  • GlobeNewswire

    Neuronetics to Present at the 31st Annual Piper Jaffray Healthcare Conference

    MALVERN, Pa., Nov. 25, 2019 -- Neuronetics, Inc. (NASDAQ:STIM), a commercial stage medical technology company focused on designing, developing and marketing products that.

  • GlobeNewswire

    Daré Bioscience Closes Previously Announced Acquisition of Microchips Biotech with a First-in-Class Wireless, User-Controlled Drug Delivery Platform

    Daré Bioscience, Inc. (NASDAQ:DARÉ), a leader in women’s health innovation, today announced the closing of the previously announced acquisition by merger of privately-held Microchips Biotech, Inc.  As a result of the transaction, Microchips is a wholly owned subsidiary of Daré. Microchips is developing an innovative, wireless, user-controlled drug delivery technology with potential utility across multiple therapeutic areas, including contraception. The application of this technology in developing a contraceptive product has been supported by the Gates Foundation in the form of approximately $17.9 million in grant funding to date.

  • PR Newswire

    Neuronetics® to Present New Depression Research at 15th Annual Neuroscience Education Institute Congress

    Data confirms NeuroStar® Advanced Therapy is a proven and safe treatment option for those with medication-resistant depression MALVERN, Pa. , Nov. 7, 2019 /PRNewswire/ -- Neuronetics, Inc. (NASDAQ: STIM), ...

  • GlobeNewswire

    Neuronetics Reports Third Quarter 2019 Financial and Operating Results

    MALVERN, Pa., Nov. 05, 2019 -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing and marketing products that.

  • GlobeNewswire

    Neuronetics® Announces Appointment of Sheryl Conley to its Board of Directors

    Neuronetics, Inc. (STIM), a commercial-stage medical technology company focused on designing, developing and marketing products that improve the quality of life for patients who suffer from psychiatric disorders, today announced the appointment of Sheryl Conley to its Board of Directors, effective immediately. Ms. Conley will be a member of the Audit Committee and after her appointment, the Neuronetics’ Board of Directors will have seven members. "We are thrilled to welcome Sheryl to the Board of Neuronetics as we look to advance our mission of improving the quality of life for patients who suffer from psychiatric disorders," said Chris Thatcher, President and CEO of Neuronetics.

  • PR Newswire

    Neuronetics® and Success TMS Partner to Increase Patient Access to Leading Depression Treatment, NeuroStar® Advanced Therapy

    MALVERN, Pa., Oct. 28, 2019 /PRNewswire/ -- Neuronetics, Inc. (STIM), a commercial stage medical technology company focused on designing, developing and marketing products that improve the quality of life for patients who suffer from psychiatric disorders, today announced a partnership with Success TMS, a healthcare provider specializing in transcranial magnetic stimulation (TMS), a non-drug, non-invasive treatment for adult patients with Major Depressive Disorder (MDD). As part of a three-year agreement, Success TMS will offer Neuronetics' NeuroStar Advanced Therapy system as its preferred TMS device at 21 locations across six states.

  • GlobeNewswire

    Neuronetics to Report Third Quarter 2019 Financial and Operating Results and Host Conference Call

    MALVERN, Pa., Oct. 22, 2019 -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing and marketing products that.

  • PR Newswire

    Neuronetics CEO Chris Thatcher to Ring Nasdaq Closing Bell on October 22 in Honor of National Depression Awareness Month

    MALVERN, Pa., Oct. 21, 2019 /PRNewswire/ -- Neuronetics, Inc. (STIM), a commercial stage medical technology company focused on designing, developing and marketing products that improve the quality of life for patients who suffer from psychiatric disorders, announced today it will ring the Nasdaq Closing Bell on October 22 in honor of National Depression Awareness Month.

  • PR Newswire

    Neuronetics® Unveils Promising New Depression Research Data at Psych Congress

    New findings confirm safety and efficacy of NeuroStar® Advanced Therapy, a non-drug depression treatment, setting the stage for future indications MALVERN, Pa. , Oct. 3, 2019 /PRNewswire/ -- Neuronetics, ...

  • PR Newswire

    Neuronetics® Honors Depression Conquerors For National Depression Awareness Month

    MALVERN, Pa., Oct. 1, 2019 /PRNewswire/ -- Neuronetics, Inc. (STIM), a commercial stage medical technology company focused on designing, developing and marketing products that improve the quality of life for patients who suffer from psychiatric disorders, is spotlighting the many faces and stories of depression to encourage an open dialogue and awareness of its non-drug treatment option in honor of National Depression Awareness Month. Sharing the stories of patient advocates who have been positively impacted by NeuroStar Advanced Therapy transcranial magnetic stimulation (TMS) treatment, Neuronetics aims to educate on an innovative, safe and effective treatment option patients can turn to when antidepressant medications fail.

  • PR Newswire

    Neuronetics® Announces Greenbrook® TMS Installation Milestone for NeuroStar® Advanced Therapy System

    MALVERN, Pa., Sept. 4, 2019 /PRNewswire/ -- Neuronetics, Inc. (STIM), a commercial stage medical technology company focused on designing, developing and marketing products that improve the quality of life for patients who suffer from psychiatric disorders, today announced that Greenbrook TMS, a NeuroStar Advanced Therapy provider with 82 treatment centers across the U.S., has installed its 100th NeuroStar system. This is a significant milestone in the availability of NeuroStar Advanced Therapy transcranial magnetic stimulation (TMS) treatment for patients. Greenbrook's Matthews, NC location now joins the growing number of practices offering NeuroStar TMS.

  • PR Newswire

    Researchers at USU Unveil Neuronetics®-supported Clinical Research for PTSD and Traumatic Brain Injury at the Military Health System Research Symposium

    MALVERN, Pa., Aug. 19, 2019 /PRNewswire/ -- Neuronetics, Inc. (STIM), a commercial stage medical technology company focused on designing, developing and marketing products that improve the quality of life for patients who suffer from psychiatric disorders, announced that researchers at the Uniformed Services University of the Health Sciences will present clinical data at the 2019 Military Health System Research Symposium (MHSRS) in Kissimmee, FL from August 19-22 from an investigator-initiated trial utilizing the Company's NeuroStar® Advanced Therapy TMS research system for PTSD and traumatic brain injury (TBI). In addition, they will present a case report of one patient treated and studied for Alzheimer's Disease.

  • GlobeNewswire

    Neuronetics Reports Second Quarter 2019 Financial and Operating Results

    MALVERN, Pa., Aug. 06, 2019 -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing and marketing products that.

  • PR Newswire

    Neuronetics® Announces First TMS Patient Treated Under New Japan Reimbursement Policy

    MALVERN, Pa., Aug. 1, 2019 /PRNewswire/ -- Neuronetics, Inc. (STIM), a commercial stage medical technology company focused on designing, developing and marketing products that improve the quality of life for patients who suffer from psychiatric disorders, announced that Kanagawa Psychiatric Center is treating the first patient in Japan using NeuroStar® Advanced Therapy under the newly approved reimbursement listing by Japan's Ministry of Health, Labour and Welfare (MHLW) and the Central Social Insurance Medical Council (Chuikyo).

  • PR Newswire

    Neuronetics® Launches TrakStar® Plus Patient Data Management System to Maximize Physician Time with Patients

    MALVERN, Pa., July 29, 2019 /PRNewswire/ -- Neuronetics, Inc. (STIM), the developer of NeuroStar® Advanced Therapy, the market leader in transcranial magnetic stimulation (TMS) for depression, announced today the launch of its TrakStar® Plus patient data management system. Based on feedback from physicians on the front lines of care who are actively treating patients with Major Depressive Disorder (MDD) with the NeuroStar device, these new features are focused on improving workflow, usability and access.

  • GlobeNewswire

    Neuronetics to Present at the 39th Annual Canaccord Genuity Growth Conference

    MALVERN, Pa., July 25, 2019 -- Neuronetics, Inc. (NASDAQ:STIM), a commercial stage medical technology company focused on designing, developing and marketing products that.

  • GlobeNewswire

    Neuronetics to Report Second Quarter 2019 Financial and Operating Results and Host Conference Call

    Neuronetics, Inc. (STIM), a commercial stage medical technology company focused on designing, developing and marketing products that improve the quality of life for patients who suffer from psychiatric disorders, today announced that it plans to release second quarter 2019 financial and operating results, and certain guidance for the third quarter and full year 2019, prior to market open on Tuesday, August 6, 2019. Chris Thatcher, Chief Executive Officer, and Stephen Furlong, Chief Financial Officer, will host a conference call to review the Company's results at 8:30 a.m. Eastern Time the same day. To listen to the conference call on your telephone, please dial (877) 472-8990 for United States callers or +1 (629) 228-0778 for international callers and reference confirmation code 6595410, approximately ten minutes prior to start time.

  • PR Newswire

    NeuroStar® Patient Outcomes Registry Has Now Surpassed 3,000 Evaluable Patients, Making It The World's Largest in Major Depressive Disorder

    MALVERN, Pa., July 8, 2019 /PRNewswire/ -- Neuronetics, Inc. (STIM) – Neuronetics, Inc., the developer of NeuroStar® Advanced Therapy, announced today that its depression outcomes registry has reached 3,223 evaluable patients, making it the largest outcomes registry in the world for Major Depressive Disorder (MDD). Launched in November 2016 for the purpose of collecting and analyzing outcomes data from treatment with NeuroStar Advanced Therapy in real-word clinical settings, the registry has surpassed the number of evaluable patients in the STAR*D study (n=2,876), making it the largest registry focused on therapies for the treatment of depression.

  • PR Newswire

    Shareholder Rights Law Firm Johnson Fistel Launches Investigations

    SAN DIEGO , July 2, 2019 /PRNewswire/ -- Shareholder Rights Law Firm Johnson Fistel, LLP is investigating potential claims for violations of federal law against the following companies that recently issued ...

  • GlobeNewswire

    Neuronetics Appoints Stephen Furlong as Chief Financial Officer

    Neuronetics, Inc. (STIM), a commercial stage medical technology company focused on designing, developing and marketing products that improve the quality of life for patients who suffer from psychiatric disorders, today announced that Stephen Furlong will become its new Chief Financial Officer and Secretary, replacing Peter Donato, who will be leaving the Company after a transition period. Mr. Furlong will assume the role of CFO and Secretary effective July 22, 2019. Steve brings valuable and highly relevant financial leadership experience with fast growing companies in the medical technology industry to Neuronetics and will be a valuable addition to the senior management team as we look to continue to drive the adoption of NeuroStar Advanced Therapy and expand our market leadership position,” said Chris Thatcher, President and Chief Executive Officer of Neuronetics.

  • GlobeNewswire

    Neuronetics to Present at the JMP Life Sciences Conference

    MALVERN, Pa., June 05, 2019 -- Neuronetics, Inc. (NASDAQ:STIM), a commercial stage medical technology company focused on designing, developing and marketing products that.

  • GlobeNewswire

    NeuroStar® Advanced Therapy Receives National Reimbursement Listing in Japan

    Neuronetics, Inc. (STIM), a commercial stage medical technology company focused on designing, developing and marketing products that improve the quality of life for patients who suffer from psychiatric disorders, announced today that Japan's Ministry of Health, Labour and Welfare (MHLW) listed reimbursement for the Company’s NeuroStar® Advanced Therapy System for the treatment of Major Depressive Disorder (MDD) in adults. MHLW and Japan's Central Social Insurance Medical Council (Chuikyo) approved reimbursement earlier this year and the listing is effective as of June 1, 2019.

  • Business Wire

    INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Neuronetics, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

    The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Neuronetics, Inc. (“Neuronetics” or “the Company”) (NASDAQ: STIM) for violations of state laws. We also encourage you to contact Brian Schall of the Schall Law Firm, 1880 Century Park East, Suite 404, Los Angeles, CA 90067, at 424-303-1964, to discuss your rights free of charge. The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.

  • Business Wire

    Glancy Prongay & Murray LLP Announces Investigation on Behalf of Neuronetics, Inc. Investors (STIM)

    Glancy Prongay & Murray LLP Announces its investigation on behalf of Neuronetics, Inc. investors concerning the Company and its directors’ and officers’ possible violations of state laws.